LRRK2 (PARK8) Mutant G2019S Antibody Blocking peptide
LRRK2 (PARK8) Mutant G2019S Antibody Blocking peptide
Product Specifications
Product Name Alternative
Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin, LRRK2, PARK8
UniProt
Q5S007
Field of Research
Cell Biology
Form
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Notes
For research use only.
Applications Notes
Synthetic peptide
AA Sequence
The synthetic peptide sequence was selected from the PARK8 region of human LRRK2 (PARK8) Mutant G2019S. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470177-100 1x 100 µL
CD50 (ICAM-3) (101-1D2), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC051429-500 1x 500 µL
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF405M conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470977-500 1x 500 µL
TGF-beta (1D11.16.8), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041820-100 1x 100 µL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401820-500 1x 500 µL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details